<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-01383605</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-24T22:58:50+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Increased bone marrow toxicity of doxorubicin bound to nanoparticles</title>
            <author role="aut">
              <persName>
                <forename type="first">Stéphane</forename>
                <surname>Gibaud</surname>
              </persName>
              <email type="md5">bfd20e53264352ec086d609b328919cf</email>
              <email type="domain">univ-lorraine.fr</email>
              <idno type="idhal" notation="string">sgibaud</idno>
              <idno type="idhal" notation="numeric">4505</idno>
              <idno type="halauthorid" notation="string">3765-4505</idno>
              <idno type="IDREF">https://www.idref.fr/069329788</idno>
              <idno type="ORCID">https://orcid.org/0000-0003-3594-0601</idno>
              <idno type="VIAF">https://viaf.org/viaf/211096616</idno>
              <idno type="ISNI">http://isni.org/isni/0000000358835222</idno>
              <affiliation ref="#struct-422739"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Andreux</forename>
                <surname>Jean-Paul</surname>
              </persName>
              <idno type="halauthorid">1070212-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Colette</forename>
                <surname>Weingarten</surname>
              </persName>
              <idno type="halauthorid">1070201-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Michèle</forename>
                <surname>Renard</surname>
              </persName>
              <idno type="halauthorid">1070213-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Patrick</forename>
                <surname>Couvreur</surname>
              </persName>
              <email type="md5">fe6b0e2c3643eb1fe364755d210fb7f0</email>
              <email type="domain">u-psud.fr</email>
              <idno type="idhal" notation="string">patrick-couvreur</idno>
              <idno type="idhal" notation="numeric">751680</idno>
              <idno type="halauthorid" notation="string">160476-751680</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-7961-5443</idno>
              <idno type="IDREF">https://www.idref.fr/033265739</idno>
              <idno type="VIAF">https://viaf.org/viaf/51777340</idno>
              <affiliation ref="#struct-1353"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Stéphane</forename>
                <surname>Gibaud</surname>
              </persName>
              <email type="md5">bfd20e53264352ec086d609b328919cf</email>
              <email type="domain">univ-lorraine.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2016-10-19 06:03:34</date>
              <date type="whenWritten">1994</date>
              <date type="whenModified">2024-04-09 10:24:12</date>
              <date type="whenReleased">2016-10-19 06:03:34</date>
              <date type="whenProduced">1994</date>
              <ref type="externalLink" target="https://api.istex.fr/ark:/67375/6H6-1PPSPZV3-V/fulltext.pdf?sid=hal"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="142148">
                <persName>
                  <forename>Stéphane</forename>
                  <surname>Gibaud</surname>
                </persName>
                <email type="md5">bfd20e53264352ec086d609b328919cf</email>
                <email type="domain">univ-lorraine.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-01383605</idno>
            <idno type="halUri">https://hal.science/hal-01383605</idno>
            <idno type="halBibtex">gibaud:hal-01383605</idno>
            <idno type="halRefHtml">&lt;i&gt;European Journal of Cancer&lt;/i&gt;, 1994, 30A (6), pp.820-826. &lt;a target="_blank" href="https://dx.doi.org/10.1016/0959-8049(94)90299-2"&gt;&amp;#x27E8;10.1016/0959-8049(94)90299-2&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">European Journal of Cancer, 1994, 30A (6), pp.820-826. &amp;#x27E8;10.1016/0959-8049(94)90299-2&amp;#x27E9;</idno>
            <availability status="restricted"/>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="UNIV-PSUD">Université Paris Sud - Paris XI</idno>
            <idno type="stamp" n="UNIV-LORRAINE">Université de Lorraine</idno>
            <idno type="stamp" n="CITHEFOR-UL">CITHEFOR Cibles thérapeutiques, formulation et expertise pré-clinique du médicament </idno>
            <idno type="stamp" n="UNIV-PARIS-SACLAY">Université Paris-Saclay</idno>
            <idno type="stamp" n="UNIV-PSUD-SACLAY" corresp="UNIV-PARIS-SACLAY">Université Paris Sud pour Paris Saclay</idno>
            <idno type="stamp" n="BMS-UL">Pôle scientifique Biologie, Médecine, Santé de l'Université de Lorraine</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Increased bone marrow toxicity of doxorubicin bound to nanoparticles</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Stéphane</forename>
                    <surname>Gibaud</surname>
                  </persName>
                  <email type="md5">bfd20e53264352ec086d609b328919cf</email>
                  <email type="domain">univ-lorraine.fr</email>
                  <idno type="idhal" notation="string">sgibaud</idno>
                  <idno type="idhal" notation="numeric">4505</idno>
                  <idno type="halauthorid" notation="string">3765-4505</idno>
                  <idno type="IDREF">https://www.idref.fr/069329788</idno>
                  <idno type="ORCID">https://orcid.org/0000-0003-3594-0601</idno>
                  <idno type="VIAF">https://viaf.org/viaf/211096616</idno>
                  <idno type="ISNI">http://isni.org/isni/0000000358835222</idno>
                  <affiliation ref="#struct-422739"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Andreux</forename>
                    <surname>Jean-Paul</surname>
                  </persName>
                  <idno type="halauthorid">1070212-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Colette</forename>
                    <surname>Weingarten</surname>
                  </persName>
                  <idno type="halauthorid">1070201-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Michèle</forename>
                    <surname>Renard</surname>
                  </persName>
                  <idno type="halauthorid">1070213-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Patrick</forename>
                    <surname>Couvreur</surname>
                  </persName>
                  <email type="md5">fe6b0e2c3643eb1fe364755d210fb7f0</email>
                  <email type="domain">u-psud.fr</email>
                  <idno type="idhal" notation="string">patrick-couvreur</idno>
                  <idno type="idhal" notation="numeric">751680</idno>
                  <idno type="halauthorid" notation="string">160476-751680</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-7961-5443</idno>
                  <idno type="IDREF">https://www.idref.fr/033265739</idno>
                  <idno type="VIAF">https://viaf.org/viaf/51777340</idno>
                  <affiliation ref="#struct-1353"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">13010</idno>
                <idno type="issn">0959-8049</idno>
                <title level="j">European Journal of Cancer</title>
                <imprint>
                  <publisher>Elsevier</publisher>
                  <biblScope unit="volume">30A</biblScope>
                  <biblScope unit="issue">6</biblScope>
                  <biblScope unit="pp">820-826</biblScope>
                  <date type="datePub">1994</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/0959-8049(94)90299-2</idno>
              <ref type="publisher">http://www.sciencedirect.com/science/article/pii/0959804994902992</ref>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en"> stem cells</term>
                <term xml:lang="en"> bone marrow</term>
                <term xml:lang="en"> cyanoacrylates</term>
                <term xml:lang="en"> drug carriers</term>
                <term xml:lang="en">doxorubicin</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv.can">Life Sciences [q-bio]/Cancer</classCode>
              <classCode scheme="halDomain" n="sdv.sp.med">Life Sciences [q-bio]/Pharmaceutical sciences/Medication</classCode>
              <classCode scheme="halDomain" n="sdv.sp.pg">Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacology</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>The in vivo myelosuppressive effects of free and polyalkylcyanoacrylate-bound doxorubicin were compared in a mouse model. After intravenous administration of 11 mg/kg body weight of doxorubicin either free or bound to polyisobutyl (doxo-PIBCA) or polyisohexylcyanoacrylate (doxo-PIHCA) nanoparticles, we studied the total and differential counts of blood, bone marrow and spleen cells; the number of granulocyte progenitors (CFU-GM) was determined by culture. Doxorubicin concentrations were measured with an HPLC method in the bone marrow and the spleen. Doxo-PIHCA nanoparticles showed the highest and longest myelosuppressive effects which correlated well with a high concentration of the drug in the bone marrow and the spleen. Moreover, it was found that PIHCA nanoparticles induced the release of colony stimulating factors, which might account for the observed increase of toxic effects of doxorubicin on bone marrow progenitors. These data also indicate that a more precise evaluation of the myelosuppressive effects of targeted formulations of anticancer drugs is needed, which may be attained by studies on bone marrow progenitors.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-422739" status="VALID">
          <idno type="IdRef">169566838</idno>
          <idno type="ISNI">0000000477690249</idno>
          <idno type="RNSR">200114728J</idno>
          <idno type="IdUnivLorraine">[UL]RNC--</idno>
          <idno type="ROR">https://ror.org/05adajg67</idno>
          <orgName>Cibles thérapeutiques, formulation et expertise pré-clinique du médicament</orgName>
          <orgName type="acronym">CITHEFOR</orgName>
          <date type="start">2012-01-01</date>
          <desc>
            <address>
              <addrLine>UL, Campus Brabois Santé, Bâtiment AB 1er étage, 9 avenue de la Forêt de Haye, BP 20199, 54505 Vandoeuvre Les Nancy Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://cithefor.univ-lorraine.fr/</ref>
          </desc>
          <listRelation>
            <relation name="UR3452" active="#struct-413289" type="direct"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-1353" status="OLD">
          <orgName>Physico-chimie, pharmacotechnie, biopharmacie</orgName>
          <orgName type="acronym">PCPB</orgName>
          <desc>
            <address>
              <addrLine>5 Rue J.B Clément 92296 CHATENAY MALABRY CEDEX</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.umr-cnrs8612.u-psud.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-92966" type="direct"/>
            <relation name="UMR8612" active="#struct-441569" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-413289" status="VALID">
          <idno type="IdRef">157040569</idno>
          <idno type="IdUnivLorraine">[UL]100--</idno>
          <idno type="ROR">https://ror.org/04vfs2w97</idno>
          <orgName>Université de Lorraine</orgName>
          <orgName type="acronym">UL</orgName>
          <date type="start">2012-01-01</date>
          <desc>
            <address>
              <addrLine>34 cours Léopold - CS 25233 - 54052 Nancy cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-lorraine.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-92966" status="OLD">
          <idno type="ROR">https://ror.org/028rypz17</idno>
          <orgName>Université Paris-Sud - Paris 11</orgName>
          <orgName type="acronym">UP11</orgName>
          <date type="end">2019-12-31</date>
          <desc>
            <address>
              <addrLine>Bâtiment 300 - 91405 Orsay cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.u-psud.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>